The Cards and Payments Industry in Austria Emerging Trends and Opportunities to 2020 Now Available at iData Insights
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>The</strong> <strong>Cards</strong> <strong>and</strong> <strong>Payments</strong> <strong>Industry</strong> <strong>in</strong> <strong>Austria</strong>:<br />
Emerg<strong>in</strong>g <strong>Trends</strong> <strong>and</strong> <strong>Opportunities</strong> <strong>to</strong> <strong>2020</strong> <strong>Now</strong><br />
<strong>Available</strong> <strong>at</strong> iD<strong>at</strong>a <strong>Insights</strong><br />
SUMMARY Delve<strong>Insights</strong> Report, Yers<strong>in</strong>ia Pestis Infections-Global API Manufacturers, Marketed <strong>and</strong><br />
Phase III Drugs L<strong>and</strong>scape, 2016 , provides comprehensive <strong>in</strong>sights about the marketed drugs, drug<br />
sales, Phase III pipel<strong>in</strong>e drugs <strong>and</strong> their API Manufacturersacross the globe. A key objective of the<br />
Yers<strong>in</strong>ia Pestis Infections Report is <strong>to</strong> underst<strong>and</strong> the market <strong>and</strong> pipel<strong>in</strong>e st<strong>at</strong>us of the drugs around the<br />
Yers<strong>in</strong>ia Pestis Infections <strong>to</strong> explore the generic development opportunities, licens<strong>in</strong>g opportunities <strong>and</strong><br />
<strong>to</strong> ga<strong>in</strong> competitive advantage on design<strong>in</strong>g pipel<strong>in</strong>e startegies. <strong>The</strong> DelveInsight s Report provides the<br />
his<strong>to</strong>rical <strong>and</strong> forecasted sales of the drugs till 2018. <strong>The</strong> Report gives <strong>in</strong>sights <strong>in</strong><strong>to</strong> p<strong>at</strong>ents provid<strong>in</strong>g the<br />
p<strong>at</strong>ent protection d<strong>at</strong>a <strong>and</strong> market<strong>in</strong>g exclusivity of all the drugs across the Yers<strong>in</strong>ia Pestis Infections.<br />
While the lead<strong>in</strong>g br<strong>and</strong>s, companies <strong>and</strong> chemicals are considered thoroughly, DelveInsight s report<br />
also provides details on the Global API Manufacturers across the globe cover<strong>in</strong>g Drug Master Fil<strong>in</strong>gs of<br />
US, Europe <strong>and</strong> API Manufacturers <strong>in</strong> Asia specifically Ch<strong>in</strong>a <strong>and</strong> India. Please note:This report requires<br />
certa<strong>in</strong> upd<strong>at</strong>es. We have all the <strong>in</strong>form<strong>at</strong>ion available but require 3 bus<strong>in</strong>ess days <strong>to</strong> complete the<br />
process <strong>and</strong> ensure it is as up-<strong>to</strong>-d<strong>at</strong>e as possible. Certa<strong>in</strong> sections <strong>in</strong> the report may be removed or<br />
altered based on the availability <strong>and</strong> relevance of d<strong>at</strong>a for the <strong>in</strong>dic<strong>at</strong>ed disease.<br />
Read more<br />
Table of Conetents<br />
1. Indic<strong>at</strong>ion Overview<br />
2. Market Drugs L<strong>and</strong>scape<br />
2.1 Marketed Drugs<br />
2.2 Marketed Details of Drugs by Applic<strong>at</strong>ion Type<br />
2.3 Marketed Details of Drugs (NDA) by Market<strong>in</strong>g St<strong>at</strong>us<br />
2.4 Marketed Details of Drugs by P<strong>at</strong>ent Expir<strong>at</strong>ion Timel<strong>in</strong>e<br />
3. Global API Manufacturers Assessment<br />
3.1 API Manufacturers by United St<strong>at</strong>es Drug Master File (US DMF) St<strong>at</strong>us<br />
3.2 API Manufacturers by US DMF St<strong>at</strong>us (Drug Specific)<br />
3.3 API Manufacturers <strong>in</strong> Europe by Country<br />
3.4 API Manufacturers <strong>in</strong> India by St<strong>at</strong>e<br />
3.5 API Manufacturers <strong>in</strong> Ch<strong>in</strong>a by Prov<strong>in</strong>ce<br />
3.6 Marketed Details of Approved Drugs by Geography<br />
4. Phase III Drugs L<strong>and</strong>scape<br />
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipel<strong>in</strong>e Drugs<br />
4.2 API Manufacturers by US DMF St<strong>at</strong>us (Drug Specific)<br />
5. Drugs Market D<strong>at</strong>a <strong>and</strong> Forecasted Sales Figure-2018
6. Marketed Drugs for Yers<strong>in</strong>ia Pestis Infections<br />
6.1 Drug Name<br />
6.1.1 Drug Description<br />
6.1.2 Global Active Pharmaceutical Manufacturers for Drug<br />
6.1.3 Approval St<strong>at</strong>us of Drug<br />
6.1.4 P<strong>at</strong>ent <strong>and</strong> Exclusivity Details for Drug<br />
6.1.5 Company Profile <strong>and</strong> F<strong>in</strong>ancials<br />
7. Phase III Drugs for Yers<strong>in</strong>ia Pestis Infections<br />
7.1 Drug Name<br />
7.1.1 Drug Description<br />
7.1.2 United St<strong>at</strong>es Drug Master File (DMF)<br />
8. Discont<strong>in</strong>ued Drugs for Yers<strong>in</strong>ia Pestis Infections<br />
9. Appendix<br />
10. Methodology<br />
11. Consult<strong>in</strong>g Services<br />
12. Contact Us<br />
13. Disclaimer<br />
Read more
Change language